Larry A. Sklar

发表

Integration of virtual and physical screening

Dan C. Fara, Tudor I. Oprea, Eric R. Prossnitz, 2006, Drug Discovery Today: Technologies.

Figure 5, Five analogues submitted to support probe SID 88095709 (CID 44640177)

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

Figure 4, Screening and Hit advancement flowchart

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2013 .

Figure 15, Overlay of dose response curves for probe ML231 (SID 99300522, CID 3392161)

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2013 .

Scheme 1, Synthesis of ML342

Larry A. Sklar, Alan S. Waggoner, Craig W. Lindsley, 2013 .

Flow cytometry systems for drug discovery and development

Eric R. Prossnitz, Bruce S. Edwards, Larry A. Sklar, 2000, Photonics West - Biomedical Optics.

Table 4, Summary of modifications for R2

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

Table 4, Summary of data from primary assay collected on hit compound CID 2950007/MLS000693334

Larry A. Sklar, J. Jacob Strouse, Chad E. Schroeder, 2010 .

Table 2, Continuation of SAR expansion on initial hit SID 85240370

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

Table 5, Summary of modifications for R4

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

Figure 16, Validated hit and SAR strategy

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2013 .

Table 3, SAR summary for modification at R2

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2013 .

Figure 6, Screening flow chart

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

Figure 5, TOR compound triage and flow chart

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2013 .

Figure 6, Schematic of screen strategy

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2013 .

Figure 11, [Detailed synthetic pathway for making probe].

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2010 .

Development of a new detection technique for fluorescence lifetime-based chemical/biological sensor arrays monitoring: dual closed-loop optoelectronic auto-oscillatory detection circuit

Emmanuil M. Rabinovich, Michael J. O'Brien, Gabriel P. Lopez, 2002, SPIE BiOS.

Figure 6, Hit scaffold and dose response curves illustrating selectivity for Cdc42

Cristian G. Bologa, Larry A. Sklar, J. Jacob Strouse, 2010 .

Table 2, Assessment of CID2950007 in Key Biological Assays (based on CPDP Flow Chart)

Larry A. Sklar, J. Jacob Strouse, Chad E. Schroeder, 2010 .

[Table, Detailed synthetic pathway for making probe].

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2010 .

Table 3, Summary of modifications for R1

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

High‐Throughput Flow Cytometry

Tudor I. Oprea, Eric R. Prossnitz, Cristian G. Bologa, 2010 .

Sample handling for kinetics and molecular assembly in flow cytometry

Eric R. Prossnitz, Bruce S. Edwards, Larry A. Sklar, 1998, Photonics West - Biomedical Optics.

Figure 9, Focus of SAR expansion efforts based on primary efflux data

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

TIN-X: target importance and novelty explorer

Tudor I. Oprea, Cristian G. Bologa, Larry A. Sklar, 2017, Bioinform..

Figure 10, General synthetic scheme for the synthesis of dihydropyrazolines

Cristian G. Bologa, Larry A. Sklar, J. Jacob Strouse, 2010 .

Figure 7, Validated hit resulting from the preliminary commercial SAR effort

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

Using FRET to quantify changes in integrin structures in human leukocytes induced by chemoattractants with multi-frequency flow cytometry

Larry A. Sklar, Jessica P. Houston, Alexandre Chigaev, 2017, BiOS.

Table 1, SAR expansion on initial hit SID 85240370

Dan C. Fara, Tudor I. Oprea, Cristian G. Bologa, 2013 .

National Flow Cytometry Resource

Larry A. Sklar, James H. Jett, Carolyn Bell-Prince, 1993 .

Badapple: promiscuity patterns from noisy evidence

Tudor I. Oprea, Larry A. Sklar, Cristian Bologa, 2016, Journal of Cheminformatics.

Figure 8, Sequence alignment of human Rac1 and Cdc42

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2010 .

[Table, Assay rationale and descriptions, table of reagents and source].

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2010 .

Real-time analysis of molecular assembly by kinetic flow cytometry

Larry A. Sklar, Hong Cai, Bruce E. Lehnert, 1998, Photonics West - Biomedical Optics.

Figure 10, TORC1 bypass cell growth analysis on the probe ML231 and SID 96099781

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2013 .

Rapid Scanning Structure-Activity Relationships in Combinatorial Data Sets: Identification of Activity Switches

Clemencia Pinilla, Bruce S. Edwards, Larry A. Sklar, 2013, J. Chem. Inf. Model..

Table 2, Summary of modifications to R1

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2013 .

[Table, Summary of Results].

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2010 .

Mining large chemical spaces in lead and drug discovery

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2006 .

Pharos: Collating protein information to shed light on the druggable genome

Rajarshi Guha, Tudor I. Oprea, Larry A. Sklar, 2016, Nucleic Acids Res..

Ultrasensitive flow cytometric analyses

Larry A. Sklar, James H. Jett, John C. Martin, 1993, Photonics West - Lasers and Applications in Science and Engineering.

Flow Cytometry

Bruce S. Edwards, Larry A. Sklar, B. Edwards, 2015, Journal of biomolecular screening.

Analysis of individual lipoproteins and liposomes

Larry A. Sklar, James H. Jett, Richard A. Keller, 1997, Photonics West - Biomedical Optics.

A quantitative approach for studying IgE–FcεRI aggregation

Larry A. Sklar, Paul B. Savage, William S. Hlavacek, 2002 .

Control of Molecular Transport Through Stimuli‐Responsive Ordered Mesoporous Materials

Larry A. Sklar, Gabriel P. Lopez, Timothy L. Ward, 2003 .

Release of Ubiquitin-Charged Cdc34-SUb from the RING Domain Is Essential for Ubiquitination

Larry A. Sklar, Tione Buranda, K. Matthew Scaglione, 2003 .

Preclinical Development of a Neutral, Estrogen Receptor–Targeted, Tridentate 99mTc(I)-Estradiol-Pyridin-2-yl Hydrazine Derivative for Imaging of Breast and Endometrial Cancers

Eric R. Prossnitz, Larry A. Sklar, Donghai Dai, 2008, Journal of Nuclear Medicine.

Profiling a Selective Probe for RTG Branch of Yeast TORC1 Signaling Pathway

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2013 .

Characterization of a Cdc42 Protein Inhibitor and Its Use as a Molecular Probe

Tudor I. Oprea, Larry A. Sklar, Chad E. Schroeder, 2013, The Journal of Biological Chemistry.

High-Throughput Screening with HyperCyt® Flow Cytometry to Detect Small Molecule Formylpeptide Receptor Ligands

Tudor I. Oprea, Eric R. Prossnitz, Bruce S. Edwards, 2005, Journal of biomolecular screening.

Three small molecule pan activator families of Ras-related GTPases

Tudor I. Oprea, Cristian G. Bologa, Bruce S. Edwards, 2010 .

Selective Chemical Inhibition of agr Quorum Sensing in Staphylococcus aureus Promotes Host Defense with Minimal Impact on Resistance

Bruce S. Edwards, Larry A. Sklar, Michael Otto, 2014, PLoS pathogens.

A small molecule pan-inhibitor of Ras-superfamily GTPases with high efficacy towards Rab7

Cristian G. Bologa, Larry A. Sklar, Chad E. Schroeder, 2013 .

A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling

Eric R. Prossnitz, Larry A. Sklar, D. Cimino, 2005, Science.

Chapter 8 Time as a flow cytometric parameter

Larry A. Sklar, L. Sklar, L. Seamer, 2001 .

Post-High-Throughput Screening Analysis: An Empirical Compound Prioritization Scheme

Tudor I. Oprea, Eric R. Prossnitz, Cristian G. Bologa, 2005, Journal of biomolecular screening.

Real-time Analysis of Very Late Antigen-4 Affinity Modulation by Shear*

Bruce S. Edwards, Larry A. Sklar, Terry D. Foutz, 2004, Journal of Biological Chemistry.

Real-time Analysis of G Protein-coupled Receptor Reconstitution in a Solubilized System*

Eric R. Prossnitz, Larry A. Sklar, Vsevolod V. Gurevich, 2001, The Journal of Biological Chemistry.

Selective Bcl-2 Inhibitor Probes

Tudor I. Oprea, Bruce S. Edwards, Larry A. Sklar, 2013 .

Unexplored therapeutic opportunities in the human genome

Anton Simeonov, Christian von Mering, Tudor I. Oprea, 2018, Nature Reviews Drug Discovery.

FRET Detection of Cellular α4-Integrin Conformational Activation

Eric R. Prossnitz, Larry A. Sklar, Alexandre Chigaev, 2003 .

Flow Cytometry Enables a High-Throughput Homogeneous Fluorescent Antibody-Binding Assay for Cytotoxic T Cell Lytic Granule Exocytosis

Larry A. Sklar, Ohyun Kwon, L. Sklar, 2013, Journal of biomolecular screening.

Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia

Larry A. Sklar, Stuart L. Schreiber, Anna Waller, 2016, Cell.

FLOW CYTOMETRY FOR BIOTECHNOLOGY

Larry A. Sklar, L. Sklar, 2005 .

A Potent and Selective Inhibitor of Cdc42 GTPase

Cristian G. Bologa, Larry A. Sklar, Chad E. Schroeder, 2010 .

Unexplored therapeutic opportunities in the human genome

Anton Simeonov, Christian von Mering, Tudor I. Oprea, 2018, Nature Reviews Drug Discovery.

Chemotactic Peptide/Complement Receptors

Eric R. Prossnitz, Larry A. Sklar, 2004 .

N-Formyl Peptide Receptor Phosphorylation Domains Differentially Regulate Arrestin and Agonist Affinity*

Eric R. Prossnitz, Larry A. Sklar, Terry D. Foutz, 2003, The Journal of Biological Chemistry.

Real Time Analysis of the Affinity Regulation of α4-Integrin

Eric R. Prossnitz, Bruce S. Edwards, Larry A. Sklar, 2001, The Journal of Biological Chemistry.

Arrestin Variants Display Differential Binding Characteristics for the Phosphorylated N-Formyl Peptide Receptor Carboxyl Terminus*

Eric R. Prossnitz, Larry A. Sklar, Vsevolod V. Gurevich, 2002, The Journal of Biological Chemistry.

The emergence of flow cytometry for sensitive, real-time measurements of molecular interactions

Larry A. Sklar, John P. Nolan, L. Sklar, 1998, Nature Biotechnology.